Clonal Evolution in Myelodysplasia and Acute Myeloid Leukaemia following Azacitidine

骨髓增生异常综合征(MDS)和急性髓系白血病(AML)代表了一系列临床上不同类型的恶性肿瘤，在绝大多数患者中仍然无法治愈。虽然支持这些恶性肿瘤的启动/维持的DNA突变在很大程度上是已知的，但我们对这些突变如何改变治疗反应知之甚少。使用一系列复杂的尖端技术，我们将研究这些DNA突变如何在治疗过程中进化。

The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a spectrum of clinically heterogeneous malignancies that remain incurable in the vast majority of patients. Whilst the DNA mutations underpinning the initiation/maintenance of these malignancies are largely known we have little insight into how these mutations alter response to therapy. Using a range of sophisticated cutting edge technologies we will study how these DNA mutations evolve over the course of treatment.